Fig. 1

Expression and prognostic value of DNMT3B in MM. (A) Comparison of the DNMT3B mRNA levels of matched newly diagnosed (ND) and relapsed (Relapse) primary samples (n = 38) from the CoMMpass study. ***p ≤ 0.001. (B) DNMT3B mRNA levels as determined by RNA-Seq in normal bone marrow plasma cells (PCs, n = 5), primary MM cells (n = 97) and HMCLs (n = 33). ***p ≤ 0.001 compared to PCs, p ≤ 0.0001 compared to MM cells. C-D) Prognostic value of DNMT3B mRNA in terms of overall survival (OS) in ND (TT3 and CoMMpass cohort, C) and relapsed patients (Mulligan and Dara cohort, D). Maxstat analysis was used to calculate the optimal separation of patients based on a cut-off value. E) Multivariate cox analysis of DNMT3B, del17p, 1q gain, del 1p and t(4;14) using the data from the CoMMpass study. This forest plot shows the hazard ratios (HR) ± 95% CI. *p ≤ 0.005, ***p ≤ 0.001 and ****p ≤ 0.0001